Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Intellectual Property, International Trade
|
Advocacy on the proposed Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1 Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays.
|
Legislative Proposal, Bill or Resolution, Regulation
|
|
Budget, Health
|
Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.
|
Policies or Program, Grant, Contribution or Other Financial Benefit
|
|
Health, International Trade
|
Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
|
Regulation, Policies or Program, Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Intellectual Property, International Trade, Research and Development
|
Contribution to the Government Public consultations on Canada-United States-Mexico Agreement to inform Canada’s priorities in preparation for the first joint review of CUSMA by Canada, the United States and Mexico in 2026 and ahead of Canada’s chairing of the 5th meeting of the CUSMA Free Trade Commission, in 2025.
|
Policies or Program, Legislative Proposal, Bill or Resolution, Regulation
|
|
Health, Intellectual Property, International Trade
|
Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver and the World Health Organization pandemic treaty proposal
|
Legislative Proposal, Bill or Resolution, Regulation, Policies or Program
|
|
Government Procurement, Health
|
Discussions on the procurement of a COVID19 vaccine and therapy
|
Grant, Contribution or Other Financial Benefit
|
|
Health, Industry
|
Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
|
Policies or Program, Regulation
|
|
Government Procurement, Health
|
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
|
Policies or Program
|
|
Health
|
Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages
|
Regulation, Policies or Program, Legislative Proposal, Bill or Resolution
|
|
Health
|
Monitoring and engaging on the Government’s commitment to create a national strategy for rare diseases; the Canadian Drug Agency; and C64, An Act to Implement pharmacare.
|
Legislative Proposal, Bill or Resolution, Regulation, Policies or Program
|
|
Health, Industry, International Trade
|
Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
|
Regulation, Policies or Program
|
|
Government Procurement
|
Monitoring and engaging the Government and Parliamentarians on the House of Commons Standing Committee on Public Accounts (PACP) motion related to the discloser on vaccine contracts
|
Legislative Proposal, Bill or Resolution
|
|
Health
|
Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines.
|
Policies or Program, Regulation
|
|
Health
|
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
|
Regulation, Policies or Program
|
|
Industry
|
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
|
Policies or Program
|
Pfizer's mission is to discover and develop innovative medicines, vaccines and other products to improve the quality of life of people and animals.
Najah Sampson, President
Address:
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QC H9J 2M5
Canada
Telephone number:
514-693-4264
Pfizer Canada ULC does not have any subsidiaries that could have a direct interest in the outcome of the undertaking